公开(公告)号：WO2008073479A3

公开(公告)日：2008-08-07

申请号：PCT/US2007025446

申请日：2007-12-11

Applicant: CODA THERAPEUTICS INC ,  BECKER DAVID L ,  GREEN COLIN R ,  DUFT BRADFORD J

Inventor： BECKER DAVID L ,  GREEN COLIN R ,  DUFT BRADFORD J

IPC: A61K31/7105 ,  A61P17/02 ,  C12N15/113

CPC classification number: C12N15/1138 ,  A61K31/7105 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/35

Abstract: Connexin modulation for the treatment of wounds that do not heal at expected rates, including delayed healing wounds, incompletely healing wounds, and chronic wounds, and associated methods, compositions and articles.

Abstract translation: 用于治疗不按预期速率愈合的伤口的连接蛋白调节剂，包括延迟愈合伤口，不完全愈合的伤口和慢性伤口，以及相关方法，组合物和制品。

公开(公告)号：WO2008073479A2

公开(公告)日：2008-06-19

申请号：PCT/US2007/025446

申请日：2007-12-11

Applicant: CODA THERAPEUTICS, INC. ,  BECKER, David, L. ,  GREEN, Colin, R. ,  DUFT, Bradford, J.

Inventor： BECKER, David, L. ,  GREEN, Colin, R. ,  DUFT, Bradford, J.

IPC: A61K31/7105 ,  C12N15/11 ,  A61P17/02

CPC classification number: C12N15/1138 ,  A61K31/7105 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/35

Abstract: Connexin modulation for the treatment of wounds that do not heal at expected rates, including delayed healing wounds, incompletely healing wounds, and chronic wounds, and associated methods, compositions and articles.

Abstract translation: 用于治疗不按预期速率愈合的伤口的连接蛋白调节剂，包括延迟愈合伤口，不完全愈合的伤口和慢性伤口，以及相关方法，组合物和制品。

公开(公告)号：WO2016029191A3

公开(公告)日：2016-08-18

申请号：PCT/US2015046425

申请日：2015-08-21

Applicant: AUCKLAND UNISERVICES LTD ,  CODA THERAPEUTICS INC

Inventor： GREEN COLIN RICHARD ,  KIM YERI ,  PHILLIPS ANTHONY ,  DUFT BRADFORD JAMES

IPC: C12N15/113 ,  A61K31/7125 ,  C07H21/02

CPC classification number: C12N15/113 ,  A61K9/0048 ,  A61K31/167 ,  A61K31/195 ,  A61K31/352 ,  A61K31/382 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/575 ,  A61K31/713 ,  A61K38/08 ,  A61K38/10 ,  A61K38/39 ,  A61K45/06 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/3231 ,  A61K2300/00

Abstract: The inventions relate to compositions and articles of manufacture comprising connexin modulators, pannexin modulators, gap junction modulators, hemichannel modulators, and pannexin channel modulators and their use, alone or in combination, in treating ocular and other disorders.

Abstract translation: 本发明涉及包含连接蛋白调节剂，pannexin调节剂，间隙连接调节剂，半通道调节剂和pannexin通道调节剂的组合物和制品以及它们单独或组合用于治疗眼部疾病和其他疾病的用途。

公开(公告)号：WO2014145342A3

公开(公告)日：2014-12-31

申请号：PCT/US2014030082

申请日：2014-03-15

Applicant: CODA THERAPEUTICS INC

Inventor： PHILLIPS ANTHONY ,  EISENBUD DAVID ,  BANNAN SCOTT ,  POOL DAVID ,  MATSUOKA GROVE ,  SUNDERLAND TRACEY ,  DUFT BRADFORD

IPC: C12N15/11 ,  C12N5/00 ,  C12N5/02

CPC classification number: A61K31/7088 ,  A61B5/0064 ,  A61B5/0077 ,  A61B5/1072 ,  A61B5/1079 ,  A61B5/1109 ,  A61B5/445 ,  A61B5/4839 ,  A61B5/4848 ,  A61B5/7275 ,  A61B2503/40 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/70 ,  A61K31/7105 ,  A61K47/00 ,  A61K47/10 ,  A61K47/38 ,  A61K48/00 ,  C07K14/47 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/30 ,  C12N2320/35

Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.

Abstract translation: 本发明涉及通过施用抗连接蛋白剂，特别是抗连接蛋白43反义多核苷酸治疗慢性伤口的改进的方法，用途和试剂盒。 本发明的方法，用途和试剂盒基于惊人的和意想不到的发现，即在预处理阶段期间，不增加或减少大小超过预定量的慢性伤口比成功治疗更适合于比 在预处理阶段，其大小在目标范围之外变化的伤口。

公开(公告)号：WO2009148613A1

公开(公告)日：2009-12-10

申请号：PCT/US2009/003408

申请日：2009-06-04

Applicant: CODA THERAPEUTICS, INC. ,  DUFT, Bradford, J. ,  GREEN, Colin

Inventor： DUFT, Bradford, J. ,  GREEN, Colin

IPC: C12N15/11 ,  A61P25/00

CPC classification number: C12N15/1138 ,  C07K14/705 ,  C12N2310/11 ,  C12N2310/14

Abstract: The present invention relates to delivery, including transdermal delivery, of a therapeutically effective amount of a compound useful for modulating gap junction formation and function, including an oligonucleotide for reducing gap junction formation and function, and methods and compositions for treating a subject suffering from pain associated with a disease, disorder or condition and associated with pain, including but not limited to muscle pain, ligament pain, tendon pain, joint pain and post-operative pain.

Abstract translation: 本发明涉及治疗有效量的用于调节间隙连接形成和功能的化合物的递送（包括透皮递送），包括用于减少间隙连接形成和功能的寡核苷酸，以及用于治疗患有疼痛的受试者的方法和组合物 与疾病，病症或病症相关并且与疼痛相关，包括但不限于肌肉疼痛，韧带疼痛，肌腱疼痛，关节疼痛和手术后疼痛。

公开(公告)号：WO2009075882A9

公开(公告)日：2009-09-17

申请号：PCT/US2008013656

申请日：2008-12-11

Applicant: CODA THERAPEUTICS INC ,  DUFT BRADFORD J

Inventor： DUFT BRADFORD J

IPC: A61K38/08 ,  C12N15/113

CPC classification number: C12N15/1138 ,  A61K38/10 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/31 ,  A61K2300/00

Abstract: Methods and compositions comprising combinations and uses of a first anti-connexin agent and a second anti-connexin agent, for example, one or more anti-connexin polynucleotides and one or more anti-connexin peptides or peptidomimetics, are provided for therapeutic use including uses for the promotion and/or improvement of wounds and wound healing and/or tissue repair.

Abstract translation: 提供包含第一抗连接蛋白药剂和第二抗连接蛋白药剂，例如一种或多种抗连接蛋白多核苷酸和一种或多种抗连接蛋白肽或肽模拟物的组合和用途的用于治疗用途的方法和组合物，包括用途 用于促进和/或改善伤口和伤口愈合和/或组织修复。

公开(公告)号：WO2009097077A3

公开(公告)日：2009-08-06

申请号：PCT/US2009/000129

申请日：2009-01-07

Applicant: CODA THERAPEUTICS, INC. ,  MORI, Ryoichi ,  MARTIN, Paul ,  DUFT, Bradford, J. ,  SHAW, Tanya

Inventor： MORI, Ryoichi ,  MARTIN, Paul ,  DUFT, Bradford, J. ,  SHAW, Tanya

IPC: C12N15/11 ,  A61K48/00

Abstract: Methods and compositions comprising an anti-ostepontin agent and/or a PDGF receptor blocker or antagonist, alone or in combination with one or more anti-connexin agents, for example, one or more anti-connexin polynucleotides and/or one or more anti-connexin peptides or peptidomimetics, are provided for the promotion and/or improvement of wound healing and/or tissue repair, and for anti-scarring, anti-inflammatory, anti-fibrosis and anti-adhesion indications.

公开(公告)号：WO2009075882A3

公开(公告)日：2009-07-30

申请号：PCT/US2008013656

申请日：2008-12-11

Applicant: CODA THERAPEUTICS INC ,  DUFT BRADFORD J

Inventor： DUFT BRADFORD J

IPC: A61K38/08 ,  C12N15/113

CPC classification number: C12N15/1138 ,  A61K38/10 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/31 ,  A61K2300/00

Abstract: Methods and compositions comprising combinations and uses of a first anti-connexin agent and a second anti-connexin agent, for example, one or more anti-connexin polynucleotides and one or more anti-connexin peptides or peptidomimetics, are provided for therapeutic use including uses for the promotion and/or improvement of wounds and wound healing and/or tissue repair.

Abstract translation: 提供包含第一抗连接蛋白剂和第二抗连接蛋白剂的组合和用途的方法和组合物，例如一种或多种抗连接蛋白多核苷酸和一种或多种抗连接蛋白肽或肽模拟物，用于治疗用途，包括用途 用于促进和/或改善伤口和伤口愈合和/或组织修复。

公开(公告)号：WO2009085273A2

公开(公告)日：2009-07-09

申请号：PCT/US2008014024

申请日：2008-12-22

Applicant: CODA THERAPEUTICS INC ,  BECKER DAVID L ,  GREEN COLIN R ,  DUFT BRADFORD J

Inventor： BECKER DAVID L ,  GREEN COLIN R ,  DUFT BRADFORD J

IPC: A61K48/00 ,  C12N15/113

CPC classification number: C12N15/1138 ,  A01K2207/05 ,  A01K2207/30 ,  A01K2227/10 ,  A01K2227/105 ,  A01K2227/107 ,  A01K2267/03 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/7007 ,  A61K47/10 ,  A61K47/12 ,  A61K47/16 ,  A61K47/186 ,  A61K47/36 ,  A61K47/38 ,  A61L31/042 ,  A61L31/145 ,  C12N2310/11

Abstract: Connexin modulation for the treatment of surgical adhesions, and associated methods, compositions, and articles.

Abstract translation: 用于治疗手术粘连的连接蛋白调节剂，以及相关方法，组合物和制品。

公开(公告)号：WO2009085271A3

公开(公告)日：2009-07-09

申请号：PCT/US2008/014022

申请日：2008-12-22

Applicant: CODA THERAPEUTICS, INC. ,  DUFT, Bradford, J.

Inventor： DUFT, Bradford, J.

IPC: C12N15/11 ,  A61K38/17 ,  A61P41/00

Abstract: Methods, compounds, compositions, kits and articles of manufacture comprising anti-connexin agents for treatment of orthopedic disorders, diseases, or conditions, and improving recoveries and outcomes of orthopedic procedures or surgeries.